Serum response factor (SRF)–YY1 complexes can bind to the promoter of ING5 and upregulate its transcription, thereby promoting lipid droplets’ (LDs) formation and increasing sorafenib resistance of HCC cells [117]. This evidence concerns the gene SRF and hepatocellular carcinoma.